Jaguar Health Q2 FY26 earnings call JAGX

Jaguar Health has undergone a significant strategic transformation, pivoting to become a rare disease GI company with 100% of its human development efforts focused on its novel crofelemer formulation for Intestinal Failure indications. This shift was enabled by the U.S. Commercial out-license agreement with Future Pak for Mytesi and Canalevia-CA1, which provided $18 million in upfront non-dilutive capital. The deal leverages Future Pak's expanded commercial reach in the HIV market, allowing Jaguar to concentrate on higher-value rare disease programs.

The company presented groundbreaking results at ESPGHAN for its liquid oral crofelemer formulation in Pediatric Intestinal Failure patients. In one MVID patient, weekly parenteral support (PS) requirements normalized to body weight were reduced by up to 48% after more than 12 months of therapy. Two SBS-IF patients saw PS requirements reduced by up to 40% over a year. These results are considered clinically stunning, far exceeding the 10-15% reduction typically considered relevant, and demonstrate a clean safety profile with no crofelemer-related issues.

Jaguar is pursuing an accelerated regulatory path for crofelemer in Pediatric Microvillus Inclusion Disease (MVID), an ultra-rare disorder with no approved therapies. The pivotal randomized double-blind, placebo-controlled trial is fully enrolled, and an amendment for a treatment-only extension phase has been authorized by the FDA. The company expects to file for Breakthrough Therapy Designation in Q4 2026 and submit the NDA in mid-2027, potentially leading to U.S. approval by the end of 2027. This strategy involves filing with a single-digit number of patients, representing approximately 4% of the affected population, which is considered relevant for ultra-rare diseases.

Following the MVID program, Jaguar is advancing crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF), a larger orphan indication with an estimated U.S. patient population of 12,500. A Phase II randomized double-blind, placebo-controlled trial is ongoing in Germany and Italy. The global market for SBS-IF is estimated to reach approximately $8 billion by 2033, significantly larger than the HIV diarrhea market. Crofelemer's non-growth hormone, antisecretory mechanism offers a paradigm-shifting opportunity, potentially as a standard of care or in conjunction with existing therapies like GLP-2s, which are used in only 5-7% of patients due to side effects.

While human health remains the primary focus, Jaguar is expanding its animal health business with the anticipated commercial launch of Neonorm Dog. This non-prescription, plant-based product supports normal stool consistency and GI fluid balance in dogs, leveraging relationships built during the promotion of Canalevia-CA1. Neonorm Dog will be available through online and animal health retail channels, including Amazon and Chewy, addressing a strong unmet need for general watery diarrhea in dogs.

The company reported Q2 2026 prescription product net revenue of $1.2 million, a 60% decrease year-over-year due to the Future Pak out-license, but offset by a $2.1 million reduction in operating expenses. License and grant revenue included $16 million upfront and an additional $2 million holdback from Future Pak, plus $43,000 from a European partner. Despite an increased net loss of $12.7 million, the strategic shift and strong clinical data position Jaguar for significant non-dilutive business development opportunities commensurate with the multi-billion dollar market potential of its rare disease programs.